Aquestive Therapeutics Inc (NASDAQ: AQST) kicked off on Monday, down -4.30% from the previous trading day, before settling in for the closing price of $3.02. Over the past 52 weeks, AQST has traded in a range of $2.24-$6.23.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -0.52%. While this was happening, its average annual earnings per share was recorded -235.60%. With a float of $77.61 million, this company’s outstanding shares have now reached $91.18 million.
Let’s determine the extent of company efficiency that accounts for 135 employees. In terms of profitability, gross margin is 69.39%, operating margin of -35.83%, and the pretax margin is -59.58%.
Aquestive Therapeutics Inc (AQST) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Aquestive Therapeutics Inc is 14.88%, while institutional ownership is 46.31%. The most recent insider transaction that took place on Nov 26 ’24, was worth 214. In this transaction Chief Operating Officer of this company sold 44 shares at a rate of $4.87, taking the stock ownership to the 0 shares. Before that another transaction happened on Mar 15 ’24, when Company’s Chief Innovation/Tech Officer sold 50,000 for $6.00, making the entire transaction worth $300,000. This insider now owns 984,476 shares in total.
Aquestive Therapeutics Inc (AQST) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -235.60% per share during the next fiscal year.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
Take a look at Aquestive Therapeutics Inc’s (AQST) current performance indicators. Last quarter, stock had a quick ratio of 5.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.57 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Looking closely at Aquestive Therapeutics Inc (NASDAQ: AQST), its last 5-days average volume was 1.17 million, which is a drop from its year-to-date volume of 1.43 million. As of the previous 9 days, the stock’s Stochastic %D was 19.80%. Additionally, its Average True Range was 0.18.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 0.68%, which indicates a significant decrease from 4.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.71% in the past 14 days, which was lower than the 62.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.71, while its 200-day Moving Average is $3.86. However, in the short run, Aquestive Therapeutics Inc’s stock first resistance to watch stands at $2.97. Second resistance stands at $3.04. The third major resistance level sits at $3.09. If the price goes on to break the first support level at $2.84, it is likely to go to the next support level at $2.79. Now, if the price goes above the second support level, the third support stands at $2.72.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
The company with the Market Capitalisation of 263.51 million has total of 91,178K Shares Outstanding. Its annual sales at the moment are 50,580 K in contrast with the sum of -7,870 K annual income. Company’s last quarter sales were recorded 13,540 K and last quarter income was -11,510 K.
